Ophthalmic Drugs Market: By Type, By Application, By End User, and Geography

Ophthalmic Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Anti-inflammatory, Anti-infective, Anti-glaucoma, Anti-allergy, Anti-VEGF agents), By Application (Retinal Disorders, Glaucoma, Dry Eye, Allergies, Infections), By End User (Hospitals, Ophthalmic Clinics, Retail Pharmacies), and Region

Ophthalmic Drugs Market size was valued at US$ 61.8 billion in 2023 and is poised to grow at a 8.3% CAGR from 2024 to 2030. Ophthalmic drugs are medications used to treat various eye conditions and diseases. The increasing prevalence of eye disorders such as glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy is expected to drive the growth of the ophthalmic drugs market over the forecast period. In addition, the aging global population and rising awareness about eye health are anticipated to boost market growth significantly. Technological advancements in drug delivery systems, such as sustained-release formulations, ocular implants, and microspheres, are revolutionizing ophthalmic treatments by improving patient compliance and treatment efficacy. For instance, in October 2021, Roche (Genentech) received FDA approval for Susvimo (ranibizumab injection), a refillable ocular implant for the treatment of wet age-related macular degeneration (AMD). Susvimo is designed to continuously deliver a customized formulation of ranibizumab over a period of months, reducing the frequency of eye injections from as often as monthly to twice per year. However, the market faces certain restraints, including the high cost of innovative ophthalmic drugs, which limits accessibility, and stringent regulatory requirements that prolong the time-to-market for new products.

Side effects associated with long-term use of certain ophthalmic medications and patent expirations of blockbuster drugs leading to generic competition also pose challenges to market growth. Despite these obstacles, the market presents numerous opportunities, particularly in emerging markets with large untapped patient populations. The development of personalized medicine in ophthalmology, increasing adoption of telemedicine and digital health solutions in eye care, and growing potential for gene therapies and stem cell treatments offer promising avenues for market expansion. Rising demand for combination therapies to enhance treatment efficacy also contributes to market opportunities. Current trends in the ophthalmic drugs market include a shift towards minimally invasive drug delivery systems, increasing focus on the development of biologics for eye disorders, and growing popularity of preservative-free formulations. The rise of artificial intelligence in drug discovery and personalized treatment plans, along with increasing collaborations between pharmaceutical companies and research institutions, are shaping the future of ophthalmic drug development.

Ophthalmic Drugs Market Key Developments:
  • In March 2023, Novartis received FDA approval for Luxturna (voretigene neparvovec-rzyl), a gene therapy for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Luxturna is the first FDA-approved gene therapy for a genetic disease and the first AAV vector gene therapy approved in the United States.

Ophthalmic Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.3%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Ophthalmic Drugs Market Dynamics

The ophthalmic drug market is primarily driven by two significant factors, the increasing prevalence of eye disorders and technological advancements in drug delivery systems. The rising incidence of eye diseases, particularly among the aging global population, is a major catalyst for market growth. Conditions such as glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are becoming more common, creating a sustained demand for effective ophthalmic treatments. This demographic trend is complemented by growing awareness about eye health, leading to earlier diagnosis and treatment of eye conditions. Simultaneously, technological innovations in drug delivery systems are revolutionizing ophthalmic therapies. The development of sustained-release formulations, such as ocular implants and microspheres, is addressing the challenge of patient compliance in long-term eye treatments. These advanced delivery methods ensure a consistent therapeutic effect over extended periods, reducing the frequency of drug administration and improving overall treatment outcomes. Such innovations are not only enhancing patient experience but also opening new avenues for treating complex eye disorders.

Ophthalmic Drugs Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 61.8 billion

Market CAGR

8.3%

By Type

  • Anti-inflammatory
  • Anti-infective
  • Anti-glaucoma
  • Anti-allergy
  • Anti-VEGF agents

By Application

  • Retinal Disorders
  • Glaucoma
  • Dry Eye
  • Allergies
  • Infections

By End User

  • Hospitals
  • Ophthalmic Clinics
  • Retail Pharmacies

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

Frequently Asked Questions

The Ophthalmic Drugs Market was valued at US$ 61.8 billion in 2023 and is expected to grow at a 8.3% CAGR from 2024 to 2030.

The Ophthalmic Drugs market is segmented based on type, application, end user, and geography.

The leading players in the global Ophthalmic Drugs market include Novartis AG, Regeneron Pharmaceuticals, Allergan (AbbVie), Bausch + Lomb, Santen Pharmaceutical Co., Ltd., Bayer AG, Pfizer Inc., Roche Holding AG, Johnson & Johnson Vision, and Sun Pharmaceutical Industries Ltd.

Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation, and a seven-year forecast is presented from 2024 to 2030.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Ophthalmic Drugs Market Introduction 
2.1.Global Ophthalmic Drugs Market  - Taxonomy
2.2.Global Ophthalmic Drugs Market  - Definitions
2.2.1.Type 
2.2.2.Application
2.2.3.End User
2.2.4.Region
3.Global Ophthalmic Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Ophthalmic Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Ophthalmic Drugs Market  By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Anti-inflammatory
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Anti-infective
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Anti-glaucoma
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Anti-allergy
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Anti-VEGF agents
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global Ophthalmic Drugs Market  By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Retinal Disorders
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Glaucoma
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Dry Eye
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Allergies
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Infections
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Ophthalmic Drugs Market  By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Ophthalmic Clinics
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Retail Pharmacies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Ophthalmic Drugs Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Ophthalmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Anti-inflammatory
9.1.2.Anti-infective
9.1.3.Anti-glaucoma
9.1.4.Anti-allergy
9.1.5.Anti-VEGF agents
9.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Retinal Disorders
9.2.2.Glaucoma
9.2.3.Dry Eye
9.2.4.Allergies
9.2.5.Infections
9.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospitals
9.3.2.Ophthalmic Clinics
9.3.3.Retail Pharmacies
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Ophthalmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Anti-inflammatory
10.1.2.Anti-infective
10.1.3.Anti-glaucoma
10.1.4.Anti-allergy
10.1.5.Anti-VEGF agents
10.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Retinal Disorders
10.2.2.Glaucoma
10.2.3.Dry Eye
10.2.4.Allergies
10.2.5.Infections
10.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospitals
10.3.2.Ophthalmic Clinics
10.3.3.Retail Pharmacies
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Ophthalmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Anti-inflammatory
11.1.2.Anti-infective
11.1.3.Anti-glaucoma
11.1.4.Anti-allergy
11.1.5.Anti-VEGF agents
11.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Retinal Disorders
11.2.2.Glaucoma
11.2.3.Dry Eye
11.2.4.Allergies
11.2.5.Infections
11.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospitals
11.3.2.Ophthalmic Clinics
11.3.3.Retail Pharmacies
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Ophthalmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Anti-inflammatory
12.1.2.Anti-infective
12.1.3.Anti-glaucoma
12.1.4.Anti-allergy
12.1.5.Anti-VEGF agents
12.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Retinal Disorders
12.2.2.Glaucoma
12.2.3.Dry Eye
12.2.4.Allergies
12.2.5.Infections
12.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospitals
12.3.2.Ophthalmic Clinics
12.3.3.Retail Pharmacies
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Ophthalmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Anti-inflammatory
13.1.2.Anti-infective
13.1.3.Anti-glaucoma
13.1.4.Anti-allergy
13.1.5.Anti-VEGF agents
13.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Retinal Disorders
13.2.2.Glaucoma
13.2.3.Dry Eye
13.2.4.Allergies
13.2.5.Infections
13.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospitals
13.3.2.Ophthalmic Clinics
13.3.3.Retail Pharmacies
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Novartis AG
14.2.2.Regeneron Pharmaceuticals
14.2.3.Allergan (AbbVie)
14.2.4.Bausch + Lomb
14.2.5.Santen Pharmaceutical Co., Ltd.
14.2.6.Bayer AG
14.2.7.Pfizer Inc.
14.2.8.Roche Holding AG
14.2.9.Johnson & Johnson Vision
14.2.10.Sun Pharmaceutical Industries Ltd.
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Novartis AG
  • Regeneron Pharmaceuticals
  • Allergan (AbbVie)
  • Bausch + Lomb
  • Santen Pharmaceutical Co., Ltd.
  • Bayer AG
  • Pfizer Inc.
  • Roche Holding AG
  • Johnson & Johnson Vision
  • Sun Pharmaceutical Industries Ltd.

Related Industry Reports